Comparative Pharmacology
Head-to-head clinical analysis: VIGADRONE versus XCOPRI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIGADRONE versus XCOPRI.
VIGADRONE vs XCOPRI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible inhibitor of GABA transaminase (GABA-T), leading to increased brain concentrations of gamma-aminobutyric acid (GABA).
XCOPRI (cenobamate) is a tetrazole derivative anticonvulsant that reduces neuronal excitability through inhibition of voltage-gated sodium channels (persistent sodium current) and positive allosteric modulation of GABA-A receptors.
Adults: 500 mg orally twice daily, may increase by 500 mg/day every week; maximum 1500 mg twice daily.
Oral, 100 mg once daily for 2 weeks, then increase to 200 mg once daily. Maximum dose 400 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in young adults; 12-15 hours in elderly; therapeutic steady-state achieved within 2-3 days.
50-70 hours, allowing once-daily dosing. Steady-state is reached in approximately 2 weeks.
Renal: 70% unchanged; hepatic metabolism: 20% (primarily via CYP4A7, not CYP450); fecal: <5%.
Primarily renal, with approximately 70% of the dose excreted as unchanged drug in urine and 30% as inactive metabolites. Fecal elimination accounts for <2%.
Category C
Category C
Anticonvulsant
Anticonvulsant